Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday. They presently have a $43.00 price objective on the stock, up from their previous price objective of $30.00. Needham & Company LLC’s target price points to a potential upside of 13.13% from the stock’s previous close.

A number of other brokerages also recently issued reports on BHVN. Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Friday, September 8th. BidaskClub raised Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $54.00 price target on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday. Morgan Stanley began coverage on Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They issued an “overweight” rating for the company. Finally, William Blair began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued an “outperform” rating and a $46.00 price target for the company. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $43.25.

Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 38.33 on Wednesday. Biohaven Pharmaceutical Holding Co has a 12 month low of $17.00 and a 12 month high of $38.86. The company has a 50 day moving average of $29.66 and a 200 day moving average of $25.95. The stock’s market capitalization is $1.38 billion.

ILLEGAL ACTIVITY NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Earns Buy Rating from Needham & Company LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/13/biohaven-pharmaceutical-holding-co-ltd-bhvn-earns-buy-rating-from-needham-company-llc.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.